Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ben-Gurion University of the Negev | OTHER |
Not provided
Not provided
Not provided
Not provided
This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in obese adults with diabetes undergoing bariatric surgery. Subjects will be randomized to receive of intranasal oxytocin or placebo (8 units 3 times daily) for 8 weeks prior surgery. Study visits include screening to determine eligibility, CGM will be connected before and after oxytocin administration, and 1 year post surgery. blood tests including oral glucose tolerance test will be done and fat samples will be taken during surgery. The investigator's hypothesis is that oxytocin administration prior bariatric surgery can induce diabetes remission in patients with diabetes
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| oxytocin | Experimental | 8 U/oxytocin three-times daily, 30 min before breakfast, lunch and dinner, using a nasal atomizer for 8 weeks |
|
| placebo | Placebo Comparator | intranasal spray containing placebo three-times daily, 30 min before breakfast, lunch and dinner, using a nasal atomizer for 8 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oxytocin | Drug | 8 weeks intranasal oxytocin 24 units per day. 8 units prior each meal. 4units/0.1 ml per puff |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with diabetes remission 1 year post surgery | HBA1C less then 6.5% without need for diabetes medication | 1 year post surgery |
| Number of participants who improved their glycemic control | increase in "Time in Range" by 10% and or decrease in HBA1C by 1 % 8 weeks from treatment | 8 weeks |
| weight loss | weight reduction - kg. | 8 weeks |
| weight loss | weight reduction - kg. | 1 year |
| obesity | change in waist circumference | 8 weeks |
| obesity | change in waist circumference | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of Insulin secretion | Increase of insulin secretion after oxytocin administration | 8 weeks |
| Rate of Insulin secretion | Increase of insulin secretion after oxytocin administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Soroka Unuversity Medical Center | Beersheba | 8410101 | Israel |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D010121 | Oxytocin |
| ID | Term |
|---|---|
| D010909 | Pituitary Hormones, Posterior |
| D010907 | Pituitary Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| placebo | Drug | 8 weeks intranasal placebo 0.6 ml per day. . 0.1 ml per puff |
|
| 1 year |
| Rate of insulin resistance | Increase of insulin sensitivity after oxytocin administration | 8 weeks |
| Rate of insulin resistance | Increase of insulin sensitivity after oxytocin administration | 1 year |
| lipids-LDL CHOLESTEROL | change in lipid profile: LDL | 8 weeks |
| lipids-LDL CHOLESTEROL | change in lipid profile: LDL | 1 year |
| lipids-HDL CHOLESTEROL | change in lipid profile: HDL | 8 weeks |
| lipids-HDL CHOLESTEROL | change in lipid profile: HDL | 1 year |
| lipids-NON HDL CHOLESTEROL | change in lipid profile: NON HDL cholesterol. triglycerides | 8 weeks |
| lipids-NON HDL CHOLESTEROL | change in lipid profile: NON HDL cholesterol. triglycerides | 1 year |
| lipids-Triglycerides | change in lipid profile: triglycerides | 8 weeks |
| lipids-Triglycerides | change in lipid profile: triglycerides | 1 year |
| blood pressure | change in systolic and diastolic blood pressure | 8 weeks |
| blood pressure | change in systolic and diastolic blood pressure | 1 year |
| urine microalbumin | Change in microalbumin/creatinin | 8 weeks |
| urine microalbumin | Change in microalbumin/creatinin | 1 year |
| HPA axis | change in cortisol | 8 weeks |
| HPA axis | change in cortisol | 1 year |
| HPA axis | change in ACTH | 8 weeks |
| HPA axis | change in ACTH | 1 year |
| systemic inflammation | changes of inflammation markers: hrCRP | 8 weeks |
| systemic inflammation | changes of inflammation markers: hrCRP | 1 year |
| systemic inflammation | changes of inflammation markers: IL-6 | 8 weeks |
| systemic inflammation | changes of inflammation markers: IL-6 | 1 year |
| systemic inflammation | changes of inflammation markers: TNFα | 8 weeks |
| systemic inflammation | changes of inflammation markers: TNFα | 1 year |
| systemic inflammation | changes of inflammation markers: IL-1α | 8 weeks |
| systemic inflammation | changes of inflammation markers: IL-1α | 1 year |
| systemic inflammation | changes of inflammation markers: IL-1RA | 8 weeks |
| systemic inflammation | changes of inflammation markers: IL-1RA | 1 year |
| systemic inflammation | changes of inflammation markers: IL-17 | 8 weeks |
| systemic inflammation | changes of inflammation markers: IL-17 | 1 year |
| systemic inflammation | changes of inflammation markers: IL-21 | 8 weeks |
| systemic inflammation | changes of inflammation markers: IL-21 | 1 year |
| systemic inflammation | changes of inflammation markers: adiponectin | 8 weeks |
| systemic inflammation | changes of inflammation markers: adiponectin | 1 year |
| systemic inflammation | changes of inflammation markers: leptin | 8 weeks |
| systemic inflammation | changes of inflammation markers:leptin | 1 year |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: E2F1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: ASK1/2 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: LC3-II | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: family of ATGs | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated:p-62 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: TRAL | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: TL-1A | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: CCL5 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated:RB1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated:LEPTIN. | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: CCL2, | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated:CCL8 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated:CD68 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: BECN1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: TFDP1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: ADIPOQ, | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: NCK2 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: TP53 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: COL6A1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: COL3A1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: KIT | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: CMA1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: RIPK1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated:TNF | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: CD36 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: IL-6 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: ELN | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: CD11C | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated:CD206 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: CD163 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: CD209 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: CTGF | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: PEPD | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: PAI-1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: BCKDHB | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated:HADHA | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: MMUT | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: ALDH6A1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: endogenous control-PGK1 | 8 weeks |
| omental and subcutaneous fat inflammation | Real time PCR - mRNA will be extracted, cDNA will be generated and the following genes will be evaluated: endogenous control PPIA | 8 weeks |
| omental and subcutaneous fat inflammation | Western blot analysis -The following proteins will be evaluated: E2F1 | 8 weeks |
| omental and subcutaneous fat inflammation | Western blot analysis -The following proteins will be evaluated: ASK1 | 8 weeks |
| omental and subcutaneous fat inflammation | Western blot analysis -The following proteins will be evaluated: p-62 | 8 weeks |
| omental and subcutaneous fat inflammation | Western blot analysis -The following proteins will be evaluated: TRAL | 8 weeks |
| omental and subcutaneous fat inflammation | Western blot analysis -The following proteins will be evaluated: TL-1A, | 8 weeks |
| omental and subcutaneous fat inflammation | Western blot analysis -The following proteins will be evaluated: PEPD | 8 weeks |
| omental and subcutaneous fat inflammation | Western blot analysis -The following proteins will be evaluated: PAI-1 | 8 weeks |
| omental and subcutaneous fat inflammation | Western blot analysis -The following proteins will be evaluated: family of ATGs | 8 weeks |
| omental and subcutaneous fat inflammation | Western blot analysis -The following proteins will be evaluated: endogenous control -beta-actin | 8 weeks |
| omental and subcutaneous fat inflammation | ELISA: adiponectin | 8 weeks |
| omental and subcutaneous fat inflammation | ELISA: leptin | 8 weeks |
| omental and subcutaneous fat inflammation | ELISA: TNF | 8 weeks |
| omental and subcutaneous fat inflammation | ELISA: IL-6 | 8 weeks |
| omental and subcutaneous fat inflammation | histological studies :Adipocyte size distribution. | 8 weeks |
| omental and subcutaneous fat inflammation | histological studies : CD68 staining | 8 weeks |
| omental and subcutaneous fat inflammation | histological studies :,c-kit staining | 8 weeks |
| omental and subcutaneous fat inflammation | Culture of explants in media for up to 1 week for obtaining medium with secreted products of the tissue. Following secreted products will be measured using ELISA: adiponectin | 8 weeks |
| omental and subcutaneous fat inflammation | Culture of explants in media for up to 1 week for obtaining medium with secreted products of the tissue. Following secreted products will be measured using ELISA: leptin | 8 weeks |
| omental and subcutaneous fat inflammation | Culture of explants in media for up to 1 week for obtaining medium with secreted products of the tissue. Following secreted products will be measured using ELISA: TNF | 8 weeks |
| omental and subcutaneous fat inflammation | Culture of explants in media for up to 1 week for obtaining medium with secreted products of the tissue. Following secreted products will be measured using ELISA: IL-6 | 8 weeks |
| omental and subcutaneous fat inflammation | Culture of explants in media for up to 1 week for obtaining medium with secreted products of the tissue. Following secreted products will be measured using ELISA: CTRP6/12/2 (ng/ml). | 8 weeks |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D006730 |
| Hormones, Hormone Substitutes, and Hormone Antagonists |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |